Background Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 observational cohort study conducted in Bihar involving 55 VL/HIV co-infected patients treated with 20–25 mg/kg intravenous liposomal amphotericin B (AmBisome) estimated an 85.5% probability of survival and a 26.5% probability of VL relapse within 2 years. Here we report the long-term field outcomes of a larger cohort of co-infected patients treated with this regimen between 2007 and 2012. Methods and Principal Findings Intravenous AmBisome (20–25 mg/kg) was administered to 159 VL/HIV co-infected patients (both primary infections and relapses) in four or five doses of 5 mg/kg over 4–10 days. Initial cure of VL at discharge was defined as improved symptoms, cessation of fever, improvement of appetite and recession of spleen enlargement. Test of cure was not routinely performed. Antiretroviral treatment (ART) was initiated in 23 (14.5%), 39 (24.5%) and 61 (38.4%) before, during and after admission respectively. Initial cure was achieved in all discharged patients. A total of 36 patients died during follow-up, including six who died shortly after admission. Death occurred at a median of 11 weeks (IQR 4–51) after starting VL treatment. Estimated mortality risk was 14.3% at six months, 22.4% at two years and 29.7% at four years after treatment. Among the 153 patients discharged from the hospital, 26 cases of VL relapse were diagnosed during follow-up, occurring at a median of 10 months (IQR 7–14) after discharge. After accounting for competing risks, the estimated risk of relapse was 16.1% at one year, 20.4% at two years and 25.9% at four years. Low hemoglobin level and concurrent infection with tuberculosis were independent risk factors for mortality, while ART initiated shortly after admission for VL treatment was associated with a 64–66% reduced risk of mortality and 75% reduced risk of relapse. Significance This is the largest cohort of HIV-VL co-infected patients reported from the Indian subcontinent. Even after initial cure following treatment with AmBisome, these patients appear to have much higher rates of VL relapse and mortality than patients not known to be HIV-positive, although relapse rates appear to stabilize after 2 years. These results extend the earlier findings that co-infected patients are at increased risk of death and require a multidisciplinary approach for long-term management.
References
[1]
World Health Organization. (1995) Report on the consultative meeting on Leishmania/HIV co-infection. report no. WHO/LEISH/95.35, pp. 1–14. Geneva: World Health Organization.
[2]
Bora D (1999) Epidemiology of visceral leishmaniasis in india. Natl Med J India 12: 62–68.
[3]
Pandey A, Sahu D, Bakkali T, Reddy D, Venkatesh S, et al. (2012) Estimate of HIV prevalence and number of people living with HIV in india 2008–2009. BMJ Open 2: e000926 doi:10.1136/bmjopen-2012-000926.
[4]
Government of India, Ministry of Health and Family Welfare. (2010) United Nations general assembly special session on HIV/AIDS country report: India.
[5]
Alexander J, Brombacher F (2012) T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: Is this paradigm still relevant? Front Immunol 3: 80 doi:10.3389/fimmu.2012.00080.
[6]
Mock DJ, Hollenbaugh JA, Daddacha W, Overstreet MG, Lazarski CA, et al. (2012) Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection. PLoS Pathog 8: e1002635 doi:10.1371/journal.ppat.1002635.
[7]
Jarvis JN, Lockwood DN (2013) Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 26: 1–9 doi:10.1097/QCO.0b013e32835c2198.
[8]
Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, et al. (2008) The relationship between leishmaniasis and AIDS: The second 10 years. Clin Microbiol Rev 21: 334–59 table of contents. doi:10.1128/CMR.00061-07.
[9]
Sinha PK, Rabidas VN, Pandey K, Verma N, Gupta AK, et al. (2003) Visceral leishmaniasis and HIV coinfection in Bihar, India. J Acquir Immune Defic Syndr 32: 115–116. doi: 10.1097/00126334-200301010-00017
[10]
Thakur CP, Narayan S, Ranjan A (2003) Kala-azar (visceral leishmaniasis) and HIV coinfection in Bihar, India: Is this combination increasing? J Acquir Immune Defic Syndr 32: 572–573. doi: 10.1097/00126334-200304150-00017
[11]
Redhu NS, Dey A, Balooni V, Singh S (2006) Leishmania-HIV co-infection: An emerging problem in India. AIDS 20: 1213–1215 doi:10.1097/01.aids.0000226971.42622.4e.
[12]
Mathur P, Samantaray JC, Vajpayee M, Samanta P (2006) Visceral leishmaniasis/human immunodeficiency virus co-infection in India: The focus of two epidemics. J Med Microbiol 55: 919–922 doi:10.1099/jmm.0.46574-0.
[13]
Thakur CP, Sinha PK, Singh RK, Hassan SM, Narain S (2000) Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in india. Trans R Soc Trop Med Hyg 94: 696–697. doi: 10.1016/s0035-9203(00)90238-4
[14]
Burza S, Mahajan R, Sanz MG, Sunyoto T, Kumar R, et al. (2014) HIV and visceral leishmaniasis co-infection in Bihar, India: An under-recognised and under-diagnosed threat against elimination. Clin Infect Dis E-pub ahead of print. doi:10.1093/cid/ciu333.
[15]
Cota GF, de Sousa MR, Fereguetti TO, Rabello A (2013) Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: A systematic review with indirect comparison. PLoS Negl Trop Dis 7: e2195 doi:10.1371/journal.pntd.0002195.
[16]
Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, et al. (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17: 493–510 doi:10.1517/14728214.2012.748036.
[17]
WHO control of the leishmaniasis (2010) Report of a meeting of the WHO expert committee on the control of leishmaniasis, 22–26 March 2010. Geneva: WHO.
[18]
Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, et al. (2014) Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (ambisome) for visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis 8: e2603 doi:10.1371/journal.pntd.0002603.
[19]
Sundar S, Rai M (2002) Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 9: 951–958. doi: 10.1128/cdli.9.5.951-958.2002
[20]
World Health Organization (2011) Field safety notice no. 1, 2011.
[21]
World Health Organization (2010) Indicators for monitoring and evaluation of the kala-azar elimination programme.
[22]
Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, et al. (2010) Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 83: 357–364 doi:10.4269/ajtmh.2010.10-0156.
[23]
Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, et al. (2011) Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53: e91 doi:10.1093/cid/cir521.
[24]
Royston P (2004) Multiple imputation of missing values. Stata Journal 4: 227–241.
[25]
Lau B, Cole SR, Gange SJ (2009) Competing risk regression models for epidemiologic data. Am J Epidemiol 170: 244–256 doi:10.1093/aje/kwp107.
[26]
Lin DY (1997) Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 16: 901–910. doi: 10.1002/(sici)1097-0258(19970430)16:8<901::aid-sim543>3.0.co;2-m
[27]
Cota GF, de Sousa MR, Rabello A (2011) Predictors of visceral leishmaniasis relapse in HIV-infected patients: A systematic review. PLoS Negl Trop Dis 5: e1153 doi:10.1371/journal.pntd.0001153.
[28]
ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: The influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46: 1702–1709 doi:10.1086/587899.
[29]
Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, et al. (2011) Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an ethiopian population with high HIV prevalence. Clin Infect Dis 53: e152–8 doi:10.1093/cid/cir674.
[30]
Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, et al. (2014) Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (ambisome) in Bihar, India. PLoS Negl Trop Dis 8: e2536 doi:10.1371/journal.pntd.0002536.
[31]
Burza S, Nabi E, Mahajan R, Mitra G, Lima MA (2013) One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India. Clin Infect Dis 57: 1363–1364 doi:10.1093/cid/cit508.
[32]
Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, et al. (2013) Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56: 1530–1538 doi:10.1093/cid/cit102.
[33]
National AIDS Control Organization (2007) Antiretroviral therapy guidelines for HIV-infected adults and adolescents, including post-exposure prophylaxis, May 2007, 125 pp.
[34]
Rai S, Mahapatra B, Sircar S, Raj PY, Venkatesh S, et al. (2013) Adherence to antiretroviral therapy and its effect on survival of HIV-infected individuals in Jharkhand, India. PLoS One 8: e66860 doi:10.1371/journal.pone.0066860.
[35]
National AIDS Control Organization And Central TB Division (2010) Ministry of health & family welfare government of India, New Delhi. TB/HIV module for ART centre staff.
[36]
National AIDS Control organisation Ministry of Health and Family Welfare Government of India (2012) Operational guidelines for ART services 2012.
[37]
van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, et al. (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10: 184–194 doi:10.1016/S1473-3099(10)70011-6.
[38]
Purkait B, Kumar A, Nandi N, Sardar AH, Das S, et al. (2012) Mechanism of amphotericin B resistance in clinical isolates of leishmania donovani. Antimicrob Agents Chemother 56: 1031–1041 doi:10.1128/AAC.00030-11.
[39]
Durand R, Paul M, Pratlong F, Rivollet D, Dubreuil-Lemaire ML, et al. (1998) Leishmania infantum: Lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis. Antimicrob Agents Chemother 42: 2141–2143.
[40]
Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, et al. (2009) Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and leishmania infantum. Clin Infect Dis 48: e16–22 doi:10.1086/595710.
[41]
Patole S, Burza S, Varghese G (2014) Multiple relapses of viceral leishmaniasis in a patient with HIV in India: A treatment challenge. International journal of infectious diseases. Int J Infect Dis E-pub ahead of print. doi:10.1016/j.ijid.2014.02.015.
[42]
Ostyn B, Gidwani K, Khanal B, Picado A, Chappuis F, et al. (2011) Incidence of symptomatic and asymptomatic leishmania donovani infections in high-endemic foci in India and Nepal: A prospective study. PLoS Negl Trop Dis 5: e1284 doi:10.1371/journal.pntd.0001284.
[43]
National vector borne disease control programme (2008) Directorate general of health services, ministry of health and family welfare. project implementation plan: National vector borne disease control support project under world bank on malaria control & kala-azar elimination (2008–2013).
